

KEY PUBLICATIONS - Zuzana Diamant - itemized per publication type

Original papers

- 2011 M. Ruddy, R. Zuiker, N. Morelli, R. Mogg, V. Rivas, K. Van Dyck, I. De Lepeleire, M. Tanen, A. Pica-Mendez, **Z. Diamant**. Detection of increased levels of Th2-derived cytokines in ultracentrifuged sputum following allergen challenge and their responsiveness to fluticasone. *ATS 2010 to be submitted to AJRCCM*.
- 2011 Nell MJ, Van Ree R, **Diamant Z**, Distler A, Boot JD. The safety, tolerability and short-term efficacy of subcutaneous mite immunotherapy in HDM-allergic patients. Abstract EAACI 2011 (manuscript in writing Q4 2011).
- 2011 Vandebriel R, Cransveld CC, Crommelin D, **Diamant Z**, Glazenburg B, Joos G, Kuper F, Natsch A, Nijkamp F, Noteborn H, Pieters R, Roberts D, Roggen E, Rorije E, Seed M, Sewald K, van den Heuvel R, van Engelen J, Verstraelen S, van Loveren H. Respiratory sensitization: Advances in assessing the risk of respiratory inflammation and irritation. *Toxicol in Vitro* 2011; Oct;25(7):1251-8.
- 2011 C. Tribouley¹, R. Zuiker³, D. Boot³, V. Malkov¹, P. Hu¹, K. Van Dyck², V. Rivas¹, G. Tokiwa¹, I. DeLepeleire², **Z. Diamant**, M. Ruddy. Allergen-induced RNA signature identified in induced sputum and in whole blood from allergic asthmatics is modulated by a short course of inhaled Fluticasone, *ATS 2010, to be submitted to J Clin Invest* (with sponsor!).
- 2010 Suppli Ulrik C, **Diamant Z**. Add-on montelukast to inhaled corticosteroids protects against excessive airway narrowing, *Clin Exp Allergy* 2010; 40: **576 – 581**.
- 2010 Zuiker RG, Boot JD, Calderon C, Piantone A, Petty K, de Kam M, **Diamant Z**. Sputum induction with hypertonic saline reduces fractional exhaled nitric oxide in chronic smokers and non-smokers. *Respir Med* 2010 Jun;104(6):917-20.
- 2009 Suppli-Ulrik C, **Diamant Z**. Effect of montelukast on excessive airway narrowing to methacholine in adult asthmatics not on controller therapy. *Allergy Asthma Proc* 2009 Jan-Feb;30(1):64-8.
- 2009 Wang WY, Boot JD, Mascelli MA, Gerth van Wijk R, **Diamant Z**. Comparison of biomarkers between allergic rhinitis only and allergic rhinitis with concomitant asthma. *Allergy* 2009 Jul;64(7):1102-3.
- 2009 Belkowski SM, Boot JD, Mascelli MA, **Diamant Z**, de Garavilla L, Hertzog B, Polkovitch D, Towers M, Batheja A, D'Andrea MR. Cleaved secretory leucocyte protease inhibitor as a biomarker of chymase activity in allergic airway disease. *Clin Exp Allergy* 2009; Aug;39(8):1179-86.
- 2008 Boot JD, Haas S de, Van Gerven JM, De Smet M, Leathem T, Wagner J, Denker A, Miller D, Van Doorn MB, Schoemaker RC, Cohen AF, **Diamant Z**. MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. *Pulm Pharmacol Ther* 2008;21(3):573-7.

- 2008 Boot JD, De Ridder L, De Kam ML, Calderon C, Mascelli MA, **Diamant Z**. Comparison of exhaled nitric oxide measurements between NIOX MINO((R)) electrochemical and Ecomedics chemiluminescence analyzer. *Respir Med* 2008;102(11):1667-71.
- 2008 Boot JD, et al, **Diamant Z**. Applicability and reproducibility of measurements of biomarkers in allergic rhinitis. *J Investig Allergol Clin Immunol* 2008;18(6):433-42.
- 2007 Boot JD, De Haas S, Tarasevych S, Roy C, Wang L, Amin D, Cohen J, Sterk PJ, Miller B, Paccaly A, Burggraaf J, Cohen AF, **Diamant Z**. Effect of an NK₁/NK₂ receptor antagonist on airway responses and inflammation to allergen in asthma. *Am J Respir Crit Care Med* 2007;175(5):450-7.
- 2007 Ravensberg AJJ, van Rensen E, Grootendorst DC, de Kluijver J, **Diamant Z**, Ricciardolo FLM and Sterk PJ. Validated safety predictions of airway responses to house dust mite in asthma. *Clin Exp Allergy* 2007;37(1):100-7.
- 2007 Boot JD, Chandoesing P, De Kam ML, Mascelli MA, Miller B, Gerth van Wijk R, De Groot H, Cohen AF, **Diamant Z**. Nasal nitric oxide: longitudinal reproducibility and the effects of a nasal allergen challenge in patients with allergic rhinitis. *Allergy* 2007;62(4):378-84.
- 2005 Cohen J, *et al*, **Diamant Z**. Airway responsiveness to neurokinin A and its relationship to methacholine in asthma. *Pulm Pharmacol Ther* 2005;18:171-6.
- 2005 Boot JD, Tarasevych S, Sterk PJ, Schoemaker RS, Wang L, Amin D, Cohen AF, **Diamant Z**. Reversal of the late asthmatic response increases exhaled nitric oxide. *Respir Med* 2005 Dec;99(12):1591-4.
- 2005 **Diamant Z**, Kuperus J, Baan R, *et al*. Effect of a very late antigen-4 antagonist on allergen-induced airway responses and inflammation in asthma. *Clin Exp Allergy* 2005;35:1080-7.
- 2000 Leckie MJ, ten Brinke A, Khan J, **Diamant Z**, *et al*, Holgate ST, Sterk PJ, Barnes PJ. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. *Lancet* 2000;356:2144-8.
- 1999*) **Diamant Z**, *et al*. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. *Clin Exp Allergy* 1999;29:42-51.
- 1997*) **Diamant Z**, *et al*. The effect of inhaled leukotriene D₄ and methacholine on cell differentials in sputum from patients with asthma. *Am J Respir Crit Care Med* 1997;155:1247-53.
- 1996*) **Diamant Z**, *et al*. The effect of inhaled thiorphan on allergen-induced airway responses in asthmatic subjects. *Clin Exp Allergy* 1996;26:525-32.
- 1996*) **Diamant Z**, *et al*. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. *Am J Respir Crit Care Med* 1996;153:1790-5.
- 1996 Schreur HJW, **Diamant Z**, *et al*. Lung sounds during allergen-induced asthmatic responses in patients with asthma. *Am J Respir Crit Care Med* 1996;153:1474-80.

- 1996 De Gouw HWFM, **Diamant Z**, *et al.* The role of neutral endopeptidase in exercise-induced bronchoconstriction in asthmatic subjects. *J Appl Physiol* 1996;81(2):673-8.
- 1996*) **Z. Diamant**: 9 October PhD-thesis: *Experimental interventions in leukotriene- and allergen-induced airway responses in asthma in vivo*. Leiden University, Leiden, The NL, Promotor: Professor Dr Peter J. Sterk.
- 1995*) **Diamant Z**, *et al.* The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects *in vivo*. *J Allergy Clin Immunol* 1995;95:42-51.
- 1995 **Diamant Z**, Van der Veen MJ, Van der Zee JS, *et al.* Prediction of the early asthmatic response to inhaled allergen from airway hyperresponsiveness to histamine, and specific IgE-RAST *versus* skin sensitivity. *Eur Respir J* 1995;8 (suppl 19):482s.
- 1994*) **Diamant Z**, *et al.* Effect of an inhaled neutral endopeptidase inhibitor, thiorphan, on airway responsiveness to LTD₄ in normal and asthmatic subjects *in vivo*. *Eur Resp J* 1994;7:459-66.
- 1988 Nieboer C, **Diamant Z** (misspelt in journal: Tak-Diamand Z), *et al.* Dustlike particles: a specific direct immunofluorescence pattern in subacute cutaneous lupus erythematosus (letter), *Br J Dermatol* 1988;118:725-29.

(*part of PhD thesis)

Case reports

- 1993 Tak PP, **Diamant Z**. Hyponatremia, hyperkalemia and hypercalcemia after ileal conduit diversion. *Scand J Urol Nephrol* 1993;27:271-74.
- 1992 **Diamant Z**, *et al.* Intra-articular rheumatoid nodules and triggering of the knee joint, *Ann Rheum Dis* 1992;51:533-35.

Expert opinions

- 2010 **Diamant Z**. Farmacologische behandeling van COPD (Dutch) – Pharmacological treatment for COPD – mini-review for gps. *Modern Medicine* 3A; 26-29.
- 2009 Bjermer L, **Diamant Z**. Complementary therapy in asthma: inhaled corticosteroids and what? *Curr Opin Pulm Med* 2009 Jan;15(1):46-51.
- 2006 **Diamant Z**, Tarasevych S, Chandoesing P, Gerth van Wijk R, de Groot H. Allergische rinitis en astma: pathofysiologische relatie en implicaties voor de behandeling. *Ned Tijdschr Geneesk* 2006;150:77-82.
- 2006 **Diamant Z**, Boot JD, Tarasevych SP, Fokkens WJ, de Groot H, Gerth van Wijk R. Verenigde luchtwegen: implicaties voor diagnostiek en behandeling van het combined allergic rhinitis and asthma syndrome'. *Ned Tijdschr Allergie* 2006;6:84-91.

- 2005 **Diamant Z**, van der Molen T. Treating asthma: is there a place for leukotriene receptor antagonists? *Respir Med* 2005;99:655-62.
- 2005 **Diamant Z**. Should pathophysiology have implications on the management of asthma? (Invited State of the Art) *Int J Respir Care* 2005;1(spring):22-7 (launching issue).
- 2004 Bjermer L, **Diamant Z**. Current and emerging nonsteroidal anti-inflammatory therapies targeting specific mechanisms in asthma and allergy. *Treat Respir Med* 2004;3:235-46.
- 2003 **Diamant Z**, Dekhuijzen PNR. Update on asthma treatment in Step2-3; *Ned Tijdschr Geneesk* 2003;147:1681-5.
- 2002 Dekhuijzen PNR, **Diamant Z**. De plaats van de leukotrienenreceptorantagonist. (*Pharmaceutisch Weekblad* 2002; jaargang 137:38-9).
- 2002 Bjermer L, **Diamant Z**. The use of leukotriene receptor antagonists (LTRAs) complementary therapy in asthma. *Monaldi Arch Chest Dis* 2002;57:76-83.
- 2002 **Diamant Z**, Dekhuijzen PNR. Astma: aandoening van de grote en kleine luchtwegen – therapeutische implicaties (letter). *Ned Tijdschr Allergie* 2002;3:107-9.
- 1999 **Diamant Z**, Sampson AP. Anti-inflammatory mechanisms of leukotriene modulators. Editorial. *Clin Exp Allergy* 1999;29:1449-53.

Reviews

- 2012 Ludviksdottir D, **Diamant Z**, Alving K, Bjermer L, Malinowski A. Clinical aspects of using exhaled nitric oxide in asthma diagnosis and management. Commissioned review *Clin Respir J* – *submitted (June 2012)*.
- 2011 **Diamant Z**, Spina D. PDE4-inhibitors: a novel targeted therapy for obstructive airways disease. *Pulm Pharmacol Ther.* 2011 Aug;24(4):353-60.
- 2011 Bjermer L, Dihal A, **Diamant Z**. Fine Particles Inhaled Corticosteroids and Systemic Therapeutic Options for the Treatment of Small Airways Inflammation in Asthma. *Commissioned Review for Treatment Strategies Respiratory* 2011, pp 34-41– *online book*.
- 2011 **Diamant Z**, Tarasevych S, Clarke G. New and existing pharmacotherapeutic options for asthma and obstructive airways disease. – commissioned expert review for *Neth J Med* 2011 Nov-Dec;69(11):486-99.
- 2010 **Diamant Z**, Boot JD, Mantzouranis E, Flohr R, Sterk PJ, Gerth van Wijk R. Biomarkers in asthma and allergic rhinitis. *Pulm Pharmacol Ther.* 2010 Dec;23(6):468-81.
- 2009 **Diamant Z**, Mantzouranis E, Bjermer L. Expert review of montelukast in the treatment of asthma and beyond. *Exp Rev Clin Immunol* 2009; 5(6); 639-658.

- 2008 **Diamant Z**, Boot JD, Kamerling I, Bjermer L. Methods used in clinical development of novel anti-asthma therapies (*Review*). *Respir Med* 2008;102(3):332-8.
- 2007 Boot JD, Panzner P, Diamant Z. A critical appraisal of methods used in early clinical development of novel drugs for the treatment of asthma. *Review*. *Pulm Pharmacol Ther* 2007;20(3):201-19.
- 2007 **Diamant Z**, Boot JD, Virchow JC. Summing up 100 years of asthma. *Review*. *Respir Med* 2007;101(3):378-88.
- 2002 Sampson AP, **Diamant Z**. Monograph on montelukast (*invited review*). *J Drug Evaluation* 2002;1(2):53-88.
- 2001 **Diamant Z**, Jöbssis Q. Leukotrienenreceptorantagonisten: een nieuwe orale klasse anti-astma medicatie. *Bijlage Ned Tijdschr Kindergeneesk*, oktober 2001.
- 2001 **Diamant Z**, Fokkens WJ. Leukotriene receptorantagonisten: clinical potential in allergic rhinitis. *Minireview*. *Rhinology* 2001;39:187-190.
- 2001 **Diamant Z**. Indicaties en mogelijkheden van leukotrienenreceptorantagonisten bij de behandeling van astma (*invited review*) *Ned Tijdschr Allergie* 2001;6:240-5.
- 2000 **Diamant Z**, Page CP. Heparin and related molecules as a new treatment for asthma. (*Review*). *Pulm Pharmacol Ther* 2000;13:1-4.
- 1999 **Diamant Z**, Duiverman EJ. Leukotrienenmodulatie bij astma. *Tijdschr Kindergeneesk* 1999;67:151-6.
- 1998 **Diamant Z**, Sterk PJ. Nieuwe therapie van asthma bronchiale: toepassing van leukotrienenreceptor antagonist en leukotrieen synthese remmers. *Ned Tijdschr Geneesk* 1998;142(2):72-8.
- 1998 **Diamant Z**, Bel EH, Dekhuijzen. Anti-leukotriene therapie in asthma. *Neth J Med* 1998;53:176-89.
- 1994*) **Diamant Z**, Lammers JW, Sterk PJ. Leukotriene receptor antagonists and biosynthesis inhibitors in asthma an update (review); *Clin Immunother* 1994;2:220-32.

Book chapters

- 2010 Rabe KF, Gillissen A, **Diamant Z**. Lung function and bronchial challenge testing for the Allergist. Chapter in series: *Allergy Frontiers: Diagnosis and Health Economics*; Eds. Pawankar R, Holgate ST, Rosenwasser LJ. 2010; Volume 4, pp 101-126.
- 2009 Dekhuijzen PNR, **Diamant Z**. Pulmonary therapeutics. Chapter on 'Respiratory tract', in *Pharmacotherapeutical textbook, Farmacologie*, 4th edition (revised), 2009.
- 2009 Bjermer L, **Diamant Z**. Update on non-steroidal, new and experimental systemic therapies for asthma. Chapter in series: *Allergy Frontiers: Therapy and Prevention*; Eds. Pawankar R, Holgate ST, Rosenwasser LJ. 2009; Volume 5, pp 465-482.

- 2004 Dekhuijzen PNR, **Diamant Z.** Pulmonary therapeutics. Chapter on 'Respiratory tract', in Pharmacotherapeutical textbook, *Farmacologie*, 3rd edition (revised), 2004.
- 2003 Spina D, Page C, Sampson AP, **Diamant Z.** Immunological functions of inflammatory mediators. Chapter in: *Immunological basis of asthma*, in series: Lung Biology in Health and Disease (Executive editor: Claude Lenfant). **Eds.** Lambrecht, Hoogsteden, **Diamant**; Marcel Dekker, Inc. New York, 2003, volume 174, pp 467-528.
- 1999 **Diamant Z**, Sampson AP. Anti-leukotriene therapy for asthma. In: Anti-inflammatory drugs in asthma. **Eds.** Sampson & Church, Birkhauser Verlag, Basel, Switzerland, 1999, pp. 169-197.
- 1999 Sampson AP, **Diamant Z.** Leukotriene Modulators. Chapter in: *New and exploratory therapeutic agents for asthma*, in series: Lung Biology in Health and Disease (Executive editor: Claude Lenfant). **Eds.** Yeadon & **Diamant**, Marcel Dekker, Inc. New York, 1999, volume 139, pp. 285-328.